斯派索利单抗--一种治疗成人泛发性脓疱型银屑病的新型白细胞介素-36抑制剂

Q1 Medicine

Skin therapy letter Pub Date : 2024-01-01

Tuba Bukhari, Mariya Markovina, Abrahim Abduelmula, Brian D Rankin, Ronald Vender, Jensen Yeung, Alim R Devani, Vimal H Prajapati

{"title":"斯派索利单抗--一种治疗成人泛发性脓疱型银屑病的新型白细胞介素-36抑制剂","authors":"Tuba Bukhari, Mariya Markovina, Abrahim Abduelmula, Brian D Rankin, Ronald Vender, Jensen Yeung, Alim R Devani, Vimal H Prajapati","doi":"","DOIUrl":null,"url":null,"abstract":"Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials.","PeriodicalId":21829,"journal":{"name":"Skin therapy letter","volume":"29 1","pages":"1-4"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.\",\"authors\":\"Tuba Bukhari, Mariya Markovina, Abrahim Abduelmula, Brian D Rankin, Ronald Vender, Jensen Yeung, Alim R Devani, Vimal H Prajapati\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials.\",\"PeriodicalId\":21829,\"journal\":{\"name\":\"Skin therapy letter\",\"volume\":\"29 1\",\"pages\":\"1-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Skin therapy letter\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Skin therapy letter","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

泛发性脓疱型银屑病（GPP）是一种罕见的免疫介导的炎症性疾病，具有特征性的皮肤和全身表现。白细胞介素-36受体拮抗剂（IL36RN）基因突变与该病的发病机制有关。Spesolimab 是一种新型的全身性生物疗法，可选择性地抑制白细胞介素-36。最近，加拿大卫生部和美国食品和药物管理局批准将其用于治疗成人 GPP 复发。1期和2期研究结果令人鼓舞。在此，我们回顾了斯派索利单抗在临床试验中用于治疗 GPP 复发的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

本刊更多论文

Spesolimab, A Novel Interleukin-36 Inhibitor for Generalized Pustular Psoriasis Flares in Adult Patients.

Generalized pustular psoriasis (GPP) is a rare, immune-mediated inflammatory disease with characteristic cutaneous and systemic manifestations. Mutations in the interleukin-36 receptor antagonist (IL36RN) gene have been implicated in its pathogenesis. Spesolimab is a novel systemic biologic therapy that selectively inhibits interleukin-36. It was recently approved by Health Canada and the US FDA for the treatment of GPP flares in adults. Results from phase 1 and 2 studies have been promising. Herein, we review the efficacy and safety of spesolimab for the treatment of GPP flares, as demonstrated in clinical trials.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Skin therapy letter Medicine-Medicine (all)

CiteScore

2.80

自引率

0.00%

发文量

期刊介绍： The premier international journal on the latest advances, techniques and practice in conservation and restoration from around the world.